123 related articles for article (PubMed ID: 34225244)
1. Is zebrafish (Danio rerio) water tank model applicable for the assessment of glucocorticoids metabolism? The budesonide assessment.
de Araujo ALD; Nunes IKDC; Sardela VF; Pereira HMG; Cabral LM; Anselmo CS
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122826. PubMed ID: 34225244
[TBL] [Abstract][Full Text] [Related]
2. Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: Progress, outlook, and challenges.
Sardela VF; Anselmo CS; Nunes IKDC; Carneiro GRA; Dos Santos GRC; de Carvalho AR; Labanca BJ; Silva Oliveira D; Ribeiro WD; de Araujo ALD; Padilha MC; de Lima CKF; de Sousa VP; de Aquino Neto FR; Gualberto Pereira HM
Drug Test Anal; 2018 Nov; 10(11-12):1657-1669. PubMed ID: 30341930
[TBL] [Abstract][Full Text] [Related]
3. Identification of budesonide metabolites in human urine after oral administration.
Matabosch X; Pozo OJ; Pérez-Mañá C; Farré M; Marcos J; Segura J; Ventura R
Anal Bioanal Chem; 2012 Aug; 404(2):325-40. PubMed ID: 22573060
[TBL] [Abstract][Full Text] [Related]
4. Phase II stanozolol metabolism study using the zebrafish water tank (ZWT) model.
Matos RR; Anselmo CS; Sardela VF; Pereira HMG
J Pharm Biomed Anal; 2021 Feb; 195():113886. PubMed ID: 33465533
[TBL] [Abstract][Full Text] [Related]
5. Metabolic study of cafestol using in silico approach, zebrafish water tank experiments and liquid chromatography high-resolution mass spectrometry analyses.
Andriolo CV; Novaes FJM; Pereira HMG; Sardela VF; Rezende CM
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Dec; 1186():123028. PubMed ID: 34801941
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Zebrafish Water Tank Experiment for Metabolic Studies of Testolactone.
Sardela VF; Sardela PDO; Lisboa RR; Matias BF; Anselmo CS; de Carvalho AR; Nunes IKC; Padilha MC; de Aquino Neto FR; Pereira HMG
Zebrafish; 2020 Apr; 17(2):104-111. PubMed ID: 32096703
[TBL] [Abstract][Full Text] [Related]
7. Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations.
Coll S; Monfort N; Matabosch X; Papakonstantinou K; Pérez-Mañá C; Mateus JA; Ventura R
Drug Test Anal; 2020 May; 12(5):629-636. PubMed ID: 31306564
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of prohibited oral use from authorized inhaled treatment of budesonide in sports.
Matabosch X; Pozo OJ; Pérez-Mañá C; Farré M; Marcos J; Segura J; Ventura R
Ther Drug Monit; 2013 Feb; 35(1):118-28. PubMed ID: 23318282
[TBL] [Abstract][Full Text] [Related]
9. Is zebrafish (Danio rerio) a tool for human-like metabolism study?
de Souza Anselmo C; Sardela VF; Matias BF; de Carvalho AR; de Sousa VP; Pereira HMG; de Aquino Neto FR
Drug Test Anal; 2017 Nov; 9(11-12):1685-1694. PubMed ID: 28987069
[TBL] [Abstract][Full Text] [Related]
10. BUDESONIDE TREATMENT OF PROFESSIONAL ATHLETES AND ANTI-DOPING TESTING--CASE STUDIES.
Kaliszewski P; Kończak D; Chołbiński P; Wicka M; Michalak D; Kwiatkowska D; Lewandowska-Pachecka S; Namieśnik J; Pokrywka A
Acta Pol Pharm; 2016; 73(1):229-37. PubMed ID: 27008817
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sulfo-conjugated and gluco-conjugated urinary metabolites for detection of methenolone misuse in doping control by LC-HRMS, GC-MS and GC-HRMS.
Fragkaki AG; Angelis YS; Kiousi P; Georgakopoulos CG; Lyris E
J Mass Spectrom; 2015 May; 50(5):740-8. PubMed ID: 26259657
[TBL] [Abstract][Full Text] [Related]
12. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
Moore CD; Roberts JK; Orton CR; Murai T; Fidler TP; Reilly CA; Ward RM; Yost GS
Drug Metab Dispos; 2013 Feb; 41(2):379-89. PubMed ID: 23143891
[TBL] [Abstract][Full Text] [Related]
13. Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS.
Matabosch X; Pozo OJ; Pérez-Mañá C; Papaseit E; Segura J; Ventura R
J Mass Spectrom; 2015 Mar; 50(3):633-42. PubMed ID: 25800201
[TBL] [Abstract][Full Text] [Related]
14. Detection of budesonide in human urine after inhalation by liquid chromatography-mass spectrometry.
Deventer K; Mikulcíková P; Van Hoecke H; Van Eenoo P; Delbeke FT
J Pharm Biomed Anal; 2006 Oct; 42(4):474-9. PubMed ID: 16842962
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice.
Yao Q; Guo Y; Xue J; Kong D; Li J; Tian X; Hao C; Zhou T
J Pharm Biomed Anal; 2020 Feb; 179():112980. PubMed ID: 31744668
[TBL] [Abstract][Full Text] [Related]
16. Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson P; Lihné M; Thalén A; Ryrfeldt A
Xenobiotica; 1987 Jan; 17(1):35-44. PubMed ID: 3825176
[TBL] [Abstract][Full Text] [Related]
17. Metabolic study of androsta-1,4,6-triene-3,17-dione in horses using liquid chromatography/high resolution mass spectrometry.
Kwok WH; Leung GN; Wan TS; Curl P; Schiff PJ
J Steroid Biochem Mol Biol; 2015 Aug; 152():142-54. PubMed ID: 26031748
[TBL] [Abstract][Full Text] [Related]
18. Metabolic study of methylstenbolone in horses using liquid chromatography-high resolution mass spectrometry and gas chromatography-mass spectrometry.
Choi TLS; Wong JKY; Kwok WH; Curl P; Mechie S; Wan TSM
J Chromatogr A; 2018 Apr; 1546():106-118. PubMed ID: 29548567
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometric characterization of toremifene metabolites in human urine by liquid chromatography-tandem mass spectrometry with different scan modes.
Lu J; Wang X; Xu Y; Dong Y; Yang S; Wu Y; Qin Y; Wu M
Analyst; 2011 Feb; 136(3):467-72. PubMed ID: 21113546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
